Neuren gains potential trofinetide protection through 2041
Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.
- US Notice of Allowance for weight-banded trofinetide dosing
- Expected protection through 28 March 2041
- Almost five-year extension to existing US protection
- Patent still requires standard administrative steps
- DAYBUE and DAYBUE STIX covered in Rett syndrome treatment
Trofinetide protection could run to 2041
Neuren Pharmaceuticals (ASX:NEU) has received a potentially valuable intellectual property boost, with partner Acadia Pharmaceuticals (Nasdaq:ACAD) reporting a US Notice of Allowance for a patent covering weight-banded dosing of trofinetide. Once issued, and including six months of paediatric exclusivity, the patent is expected to protect trofinetide in the United States through 28 March 2041.
Allowance is not yet an issued patent
The distinction matters. The United States Patent and Trademark Office has determined that application No. 17/590,496 meets the requirements for patentability, but the patent still needs to complete standard administrative steps before it is formally granted. Neuren therefore describes the 2041 date as expected protection rather than a completed legal outcome.
New claims cover marketed dosing regimen
The application covers the weight-banded dosing regimen used for DAYBUE and DAYBUE STIX, Acadia’s US products for adults and children aged two and older with Rett syndrome. Trofinetide already has a US method-of-use patent for Rett syndrome that expires in July 2036, making the proposed protection period almost five years longer than that existing patent coverage.
For Neuren, the filing is relevant because trofinetide is licensed exclusively to Acadia worldwide, while the company’s commercial model includes economics from the product’s development and sales. The announcement provides no revised royalty forecast, revenue guidance or estimate of the financial value of the additional protection, so its effect on earnings cannot be quantified from this update alone.
Patent issuance becomes the next checkpoint
The immediate catalyst is formal issuance and the final scope of the granted claims. The longer-term question is whether the additional protection helps sustain the commercial life of DAYBUE and DAYBUE STIX in the US, while Neuren continues advancing NNZ-2591 through its Phase 3 Koala trial in children with Phelan-McDermid syndrome.
Bottom Line?
The 2041 date strengthens the potential durability of trofinetide’s US franchise, but the value of the extension remains contingent on patent issuance and future commercial performance.
Questions in the middle?
- When will the USPTO formally issue the patent, and will the granted claims match the current application?
- How much commercial value could the additional US protection create for Neuren’s licensing economics?
- Can Neuren’s NNZ-2591 pipeline develop into a meaningful second growth driver alongside trofinetide?
